BioCryst Pharmaceuticals (NASDAQ:BCRX) Earns “Buy” Rating from HC Wainwright

BioCryst Pharmaceuticals (NASDAQ:BCRX)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $32.00 target price on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 224.38% from the company’s current price.

Several other equities analysts have also weighed in on BCRX. Citizens Jmp raised their target price on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a report on Thursday, May 7th. Weiss Ratings reiterated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research note on Monday, June 1st. Needham & Company LLC lowered their price objective on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Cantor Fitzgerald raised their price objective on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Tuesday. Finally, Wall Street Zen lowered BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $21.00.

BioCryst Pharmaceuticals Stock Up 3.3%

BCRX stock traded up $0.32 during trading hours on Tuesday, hitting $9.87. The company’s stock had a trading volume of 1,732,538 shares, compared to its average volume of 5,184,810. The company has a market capitalization of $2.51 billion, a PE ratio of -5.54 and a beta of 0.57. BioCryst Pharmaceuticals has a 12 month low of $6.00 and a 12 month high of $10.94. The stock has a 50 day moving average price of $8.90 and a two-hundred day moving average price of $8.27.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The business had revenue of $156.41 million for the quarter, compared to the consensus estimate of $151.12 million. During the same quarter in the prior year, the business posted $0.20 EPS. The firm’s revenue for the quarter was up 7.5% compared to the same quarter last year. Sell-side analysts expect that BioCryst Pharmaceuticals will post -2.66 earnings per share for the current year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in BCRX. Larson Financial Group LLC lifted its position in shares of BioCryst Pharmaceuticals by 1,188.0% during the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 3,267 shares during the last quarter. Focus Partners Wealth bought a new position in BioCryst Pharmaceuticals in the 3rd quarter worth approximately $77,000. Mirae Asset Global Investments Co. Ltd. increased its position in BioCryst Pharmaceuticals by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after buying an additional 2,115 shares during the period. Envestnet Portfolio Solutions Inc. acquired a new position in shares of BioCryst Pharmaceuticals during the fourth quarter worth approximately $81,000. Finally, Mercer Global Advisors Inc. ADV acquired a new position in shares of BioCryst Pharmaceuticals during the third quarter worth approximately $81,000. 85.88% of the stock is owned by institutional investors and hedge funds.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.